Treatment of Alcohol Use Disorder

Initial Assessment and Treatment Selection

The American Association for the Study of Liver Diseases recommends screening for liver disease to determine medication selection 2, 3
For patients without liver disease, naltrexone 50 mg daily is the preferred first-line pharmacotherapy, as recommended by the American College of Physicians 1
For patients with alcoholic liver disease, acamprosate or baclofen are recommended options, as naltrexone is contraindicated due to hepatotoxicity risk, according to the American Association for the Study of Liver Diseases 2, 3, 1

The American College of Emergency Physicians recommends benzodiazepines as the gold standard for alcohol withdrawal syndrome, as they reduce withdrawal symptoms and the risk of seizures and delirium tremens 4, 5
Long-acting benzodiazepines provide superior protection against seizures and delirium, as stated by the American Society of Addiction Medicine 4, 5, 6
Short/intermediate-acting benzodiazepines are safer in elderly patients and those with hepatic dysfunction, according to the American Geriatrics Society 4, 5, 6
Benzodiazepine treatment should be limited to 7-10 days to avoid dependence, as recommended by the American College of Physicians 6
Thiamine supplementation should always be provided to prevent Wernicke's encephalopathy, as stated by the American Academy of Neurology 6

Naltrexone is recommended for patients without liver disease, with a dosing of 50 mg daily orally or 380 mg monthly intramuscular injection, according to the American College of Physicians 2, 3
Acamprosate is recommended for patients with liver disease, with a dosing of 666 mg three times daily, as stated by the American Association for the Study of Liver Diseases 2, 3, 6
Baclofen has the strongest evidence among medications for patients with alcoholic liver disease, with a dosing of 30-60 mg daily, according to the American Association for the Study of Liver Diseases 2, 3, 1

Cognitive Behavioral Therapy (CBT) is the first-line behavioral approach and should be combined with pharmacotherapy, as recommended by the American Psychological Association 3, 1
Motivational interviewing is particularly effective for patients ambivalent about cessation, according to the American Society of Addiction Medicine 2, 3, 1
Family/couples counseling and group therapy, such as Alcoholics Anonymous, are also recommended, as stated by the American Association for Marriage and Family Therapy 2, 3, 6

The American College of Physicians recommends screening for liver disease and initiating benzodiazepines for acute withdrawal, followed by naltrexone or acamprosate for relapse prevention, with a treatment duration of 3-6 months 1, 2, 3, 6

The American Society of Addiction Medicine recommends never relying solely on pharmacotherapy without behavioral interventions, as this significantly reduces treatment effectiveness 1
Naltrexone should never be used in patients with active liver disease due to hepatotoxicity risk, as stated by the American Association for the Study of Liver Diseases 4, 2, 5, 1
Treatment should never be discontinued prematurely, and family dynamics and social support systems should always be addressed, according to the American College of Physicians 1, 6